Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eli Lilly and Company
Incyte Corporation
National Cancer Institute (NCI)
Children's Oncology Group
Pfizer
National Institutes of Health Clinical Center (CC)
Dana-Farber Cancer Institute
Regeneron Pharmaceuticals
Medical College of Wisconsin
National Cancer Institute (NCI)
BeiGene
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Children's Oncology Group
National Cancer Institute (NCI)
Children's Oncology Group
Radiation Therapy Oncology Group
Blaze Bioscience Inc.
EMD Serono
Celgene
Memorial Sloan Kettering Cancer Center
St. Jude Children's Research Hospital
National Cancer Institute (NCI)
Stanford University
Children's Oncology Group
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
European Organisation for Research and Treatment of Cancer - EORTC
Radiation Therapy Oncology Group
Eisai Inc.
Canadian Cancer Trials Group
City of Hope Medical Center
OHSU Knight Cancer Institute
Johns Hopkins All Children's Hospital
TVAX Biomedical
TVAX Biomedical
St. Jude Children's Research Hospital
Children's Oncology Group
Radiation Therapy Oncology Group
National Cancer Institute (NCI)
Massachusetts General Hospital
M.D. Anderson Cancer Center
University of South Florida
Eli Lilly and Company
University of South Florida
National Cancer Institute (NCI)